PIIND - PI Industries Limited Share Price

Management's outlook for PI Industries reflects cautious optimism, driven by signs of stabilization in the global AgChem market and anticipated gradual recovery. Key points from the management's guidance include a projected sequential improvement in performance beginning in Q4 FY26, with expectations of volume growth over the next quarters. For FY27, the management expressed confidence in returning to revenue growth, influenced by the commercialization of 8 to 10 new molecules, including 5 already commercialized.

Specific figures highlight that for Q3 FY26, the company reported revenues of INR 13,757 million, with a gross margin of 59% and EBITDA margins of 27% for the nine-month period ending December 31, 2025. The expectation is set for FY27 to see improved domestic growth as market dynamics normalize, leveraging a strong product portfolio supported by new launches.

Management aims for a long-term gross margin between 50% to 52%, despite recent pressures affecting pricing. They also mentioned a significant inventory level, with contract assets at INR 1,065 crore. The debt-free balance sheet, with net cash of INR 35 billion, positions the company favorably for strategic investments.

The pharma segment demonstrated a 50% year-on-year growth, while investments in biologicals are expected to yield a scalable global franchise, with regulatory approvals anticipated, including the first NCE Pioxaniliprole set for commercialization in the upcoming financial year. The management remains committed to enhancing relationships with strategic clients globally, particularly in the competitive AgChem landscape, to drive future growth.

Questions and Answers from the Earnings Call Q&A Session

1. Question: "When you say growth resuming in fourth quarter, is it only a sequential growth that you are talking about or do you even expect a Y-o-Y growth? And what type of growth is it"”volume, revenue, or value?"

Answer: "There will be volume growth starting in quarter 4 FY26, and yes, we expect sequential growth over quarter 3. As we move into FY27, we should witness a strong growth momentum driven by our initiatives."

2. Question: "Are you already seeing enough visibility from customers for a recovery in FY27, or is it based on general optimism?"

Answer: "We receive visibility from our global customers, but external factors still play a role. While some adverse headwinds persist, we observe an uptick in demand. There's optimism from our customer engagements moving forward."

3. Question: "What kind of gross margin do you expect on a sustainable basis?"

Answer: "We aim to maintain a long-term gross margin guidance between 50% to 52%. While current margins are favorable, product mix changes will always impact quarter-to-quarter expectations."

4. Question: "What's the current status of the contract assets number on the balance sheet at the end of December 2025?"

Answer: "As of this quarter, our contract assets are approximately INR 1,065 crore compared to just under INR 900 crore last quarter. We anticipate a decline as we approach year-end, contingent on customer shipments."

5. Question: "What updates do you have on the Plant Healthcare acquisition and the cross-selling of products?"

Answer: "We've expanded significantly in the U.S., Brazil, and Mexico, with many distributors and farmers testing our products. Progress includes successful product trials with a high win rate, contributing to considerable growth prospects."

6. Question: "When do you expect Pioxaniliprole to be commercialized in the Indian market?"

Answer: "We should achieve registration within the next financial year, marking a significant milestone as India's first Ag-Chem innovation. Global registrations are also underway to launch the product once approved."

7. Question: "How should we think about investments in the pharma and biologicals segments given the EBITDA losses?"

Answer: "The investments in pharma and biologicals are strategic for long-term value creation. Although current losses are evident, establishing these foundations is crucial, and we expect to see positive movement in the coming quarters."

8. Question: "Can you provide guidance on CAPEX plans for FY27?"

Answer: "Broadly, we anticipate CAPEX to be around INR 500 crore to INR 600 crore. We will provide more precise guidance after Board approval in the next quarter."

9. Question: "What is the contribution of Biologicals to fiscal 2026 revenues so far?"

Answer: "Biologicals account for around 20% of our revenue this fiscal, and we are optimistic about growth as regulatory challenges get resolved."

10. Question: "What improvements do you expect in working capital days going forward?"

Answer: "Our working capital days have increased in response to current market conditions, but we expect improvements as the market stabilizes and normalizes in the upcoming quarters."